- Home
- KURA vs ERAS Comparison
KURA vs ERAS Comparison
Compare KURA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | ERAS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KURA | ERAS |
|---|---|---|
| Price | $10.36 | $3.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $25.00 | $3.71 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $138.16 | N/A |
| Revenue Next Year | $66.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $1.01 |
| 52 Week High | $12.49 | $3.80 |
Technical Indicators
Market Signals| Indicator | KURA | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 64.17 |
| Support Level | $9.68 | $3.39 |
| Resistance Level | $11.28 | $3.77 |
| Average True Range (ATR) | 0.49 | 0.25 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 42.50 | 78.70 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.